Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Quest Diagnostics (DGX) stock climbed slightly today, gaining just above 0% after a relatively quiet session. Investors seem to be weighing recent performance, as shares are up 17% year-to-date and ...

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings results.

Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...

Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) will be reporting earnings this Tuesday before market hours. Here’s what you need to know. Quest beat analysts’ revenue expectations by 1.4% ...

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...

Strong growth, raised guidance, and new partnerships signal continued momentum amid regulatory and cost headwinds.

In just one week, Secaucus-based Quest Diagnostics announced two new product offerings: one for at-home consumer use and another for physicians. The consumer product, Genetic Insights, helps people ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive ...